Here are the 10-K annual reports from CV Sciences Inc (CVSI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CVSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVSI filings page.
CV Sciences, Inc. reported 2025 net product sales of $13.8 million, down 12.2% from 2024, while improving gross margin to 49.0% from 45.6%. The company narrowed its net loss to $0.96 million from $2.39 million, helped by cost reductions and lower operating expenses.
The business added plant-based food and softgel manufacturing through the Cultured Foods and Elevated Softgels acquisitions and launched new brands, with products sold in about 2,500 U.S. stores and across Europe. Despite this, cash was $0.28 million and management disclosed substantial doubt about its ability to continue as a going concern, citing intense CBD competition and significant regulatory uncertainty, including a new federal “total THC” cap effective November 2026.